Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KURT R OELKE

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1962433136
CMS profile
224449
Location
GLENDALE, WI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$115,649.42

211 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 5 of 5; records 201–211 of 211 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KURT R OELKE

NPI 1962433136 · CMS profile ID 224449

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

GLENDALE, WI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–211 of 211 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962433136?year=2023&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KURT R OELKE, NPI 1962433136, CMS profile ID 224449. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–211 of 211 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962433136?year=2023&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). KURT R OELKE, NPI 1962433136, CMS profile ID 224449. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–211 of 211 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962433136?year=2023&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
KURT R OELKE, NPI 1962433136, CMS profile ID 224449, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–211 of 211 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1962433136?year=2023&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

211 matching records · $115,649.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 211 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–211 of 211.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $24.5002/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015517375 CMS
ABBVIE INC. $1,500.0001/30/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998036409 CMS
Lilly USA, LLC $28.3201/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031757633 CMS
E.R. Squibb & Sons, L.L.C. $2,750.0001/23/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015517215 CMS
PFIZER INC. $18.7101/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050541733 CMS
Lilly USA, LLC $24.1701/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031852607 CMS
AstraZeneca Pharmaceuticals LP $1,850.0001/09/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015980103 CMS
AstraZeneca Pharmaceuticals LP $600.0001/09/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016052661 CMS
ABBVIE INC. $13.8001/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998036407 CMS
Horizon Therapeutics plc $24.6001/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987053683 CMS
Janssen Scientific Affairs, LLC $3,850.0001/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988547375 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $170,649.36 333
PY2020 $52,916.77 99
PY2021 $66,107.95 184
PY2022 $136,478.03 243
PY2023 $115,649.42 211
PY2024 $96,571.26 206
PY2025 $111,646.52 259

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $294,085.92 37
PY2024 Principal investigator $183,224.80 14
PY2023 Recipient $780.00 1
PY2023 Principal investigator $200,753.21 17
PY2022 Recipient $4,760.00 3
PY2022 Principal investigator $66,145.18 21
PY2021 Principal investigator $79,044.34 32
PY2020 Recipient $432.90 1
PY2020 Principal investigator $122,508.13 46
PY2019 Recipient $3,141.67 1
PY2019 Principal investigator $122,265.21 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

37 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,822.90 12/04/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202528514
Principal investigator 1 GlaxoSmithKline, LLC. $16,710.30 11/05/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE CENTER
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192141553
Principal investigator 1 ABBVIE INC. $290.40 11/04/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202520141
Principal investigator 1 ABBVIE INC. $8,350.90 11/04/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202520143
Principal investigator 1 ABBVIE INC. $1,734.70 10/09/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202516031
Principal investigator 1 GlaxoSmithKline, LLC. $5,022.00 10/02/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE CENTER
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192141745
Principal investigator 1 ABBVIE INC. $131.30 09/03/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202507345
Principal investigator 1 GlaxoSmithKline, LLC. $8,955.90 09/03/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE CENTER
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192141559
Principal investigator 1 GlaxoSmithKline, LLC. $9,634.00 08/26/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE CENTER
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192141733
Principal investigator 1 ABBVIE INC. $1,070.20 08/05/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202501832
Principal investigator 1 GlaxoSmithKline, LLC. $11,610.90 08/01/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE CENTER
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192141759
Principal investigator 1 ABBVIE INC. $2,790.60 07/02/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202496015
Principal investigator 1 ABBVIE INC. $13,093.20 07/02/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202496017
Principal investigator 1 GlaxoSmithKline, LLC. $2,187.90 07/02/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE CENTER
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192141548
Principal investigator 1 GlaxoSmithKline, LLC. $10,678.50 06/04/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE CENTER
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192141541
Principal investigator 1 ABBVIE INC. $1,666.40 06/03/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202488903
Principal investigator 1 ABBVIE INC. $911.25 06/03/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202488905
Principal investigator 1 Eli Lilly and Company $6,347.00 05/23/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE CENTER
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187889288
Principal investigator 1 UCB SA $399.33 05/21/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE CENTER
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246659515
Principal investigator 1 GlaxoSmithKline, LLC. $7,119.90 05/09/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE CENTER
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192141770
Principal investigator 1 ABBVIE INC. $3,447.45 05/06/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202481225
Principal investigator 1 ABBVIE INC. $8,481.20 05/06/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202481227
Principal investigator 1 ABBVIE INC. $1,822.90 04/03/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202472803
Principal investigator 1 ABBVIE INC. $124.80 04/03/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202472807
Principal investigator 1 GlaxoSmithKline, LLC. $3,837.60 04/02/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE CENTER
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192141764
Principal investigator 1 UCB SA $80,045.00 03/26/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE CENTER LLP
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246657638
Principal investigator 1 GlaxoSmithKline, LLC. $14,112.00 03/07/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE CENTER
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192141753
Principal investigator 1 ABBVIE INC. $3,248.70 03/06/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202458576
Principal investigator 1 ABBVIE INC. $825.80 03/06/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202458696
Principal investigator 1 ABBVIE INC. $1,746.30 02/05/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202444618
Principal investigator 1 ABBVIE INC. $4,986.00 02/05/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202444622
Principal investigator 1 Eli Lilly and Company $2,000.00 02/05/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE CENTER
TALTZ PSA OBSERVATIONAL STUDY No dispute reported 06/30/2026 1187889286
Principal investigator 1 GlaxoSmithKline, LLC. $7,856.10 02/05/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE CENTER
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192141739
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $41,505.09 01/08/2025 Non-covered Recipient Entity
Rheumatic Disease Center
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment No dispute reported 06/30/2026 1235994231
Principal investigator 1 GlaxoSmithKline, LLC. $6,263.10 01/08/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE CENTER
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192141776
Principal investigator 1 ABBVIE INC. $1,812.90 01/02/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202434312
Principal investigator 1 ABBVIE INC. $1,443.40 01/02/2025 Non-covered Recipient Entity
RHEUMATIC DISEASE
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202434316